Electrolytes & blood pressure (대한전해질대사연구회지)

The Korean Society of Electrolyte Metabolism (전해질고혈압연구회)
권호 표지
DOI QR코드

DOI QR Code

Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea

  • Kim, Ha Yeon (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Lee, Seung Jin (Department of radiology, Chonnam National University Medical School) ;
  • Kim, Byung Ki (Department of Internal Medicine, Saint Carollo Hospital) ;
  • Kim, Minah (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Bae, Eun Hui (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Ma, Seong Kwon (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Kim, Soo Wan (Department of Internal Medicine, Chonnam National University Medical School)
  • Received : 2018.12.04
  • Accepted : 2019.02.26
  • Published : 2018.12.30
⟨ Previous Next ⟩

Abstract

A 22-year-old male patient was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). He received conservative treatment with an angiotensin-converting enzyme inhibitor. Two years later, oral therapy, consisting of 60 mg tolvaptan per day, was initiated. Compared with height-adjusted total kidney volume, the rate of kidney growth reduced significantly from 7.33% to 0.66% annually, since commencement of the tolvaptan therapy. The liver enzyme profile and serum sodium level and osmolality were constantly within normal ranges. In Korea, this is the first reported case of a patient with ADPKD who received tolvaptan treatment for more than 1 year. This case demonstrates that long-term tolvaptan treatment appears to be safe, well tolerated, and effective for ADPKD.

Keywords

Acknowledgement

Supported by : Chonnam National University Hospital

References

  1. Levey AS, Stevens LA, Schmid CH, et al.: A new equation to estimate glomerular filtration rate. Annals of internal medicine 150:604-612, 2009 https://doi.org/10.7326/0003-4819-150-9-200905050-00006
  2. Gabow PA: Autosomal dominant polycystic kidney disease. Am J Kidney Dis 22:511-512, 1993 https://doi.org/10.1016/S0272-6386(12)80921-8
  3. Gattone VH, 2nd, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323-1326, 2003 https://doi.org/10.1038/nm935
  4. Gabow PA: Autosomal dominant polycystic kidney disease. N Engl J Med 329:332-342, 1993 https://doi.org/10.1056/NEJM199307293290508
  5. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369:1287-1301, 2007 https://doi.org/10.1016/S0140-6736(07)60601-1
  6. Rieg T, Tang T, Murray F, et al.: Adenylate cyclase 6 determines cAMP formation and aquaporin-2 phosphorylation and trafficking in inner medulla. J Am Soc Nephrol 21:2059-2068, 2010 https://doi.org/10.1681/ASN.2010040409
  7. Torres VE, Chapman AB, Devuyst O, et al.: Investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407-2418, 2012 https://doi.org/10.1056/NEJMoa1205511
  8. Torres VE, Chapman AB, Devuyst O, et al.: Investigators: Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 377:1930-1942, 2017 https://doi.org/10.1056/NEJMoa1710030
  9. Grantham JJ, Torres VE, Chapman AB, et al.: Investigators: Volume progression in polycystic kidney disease. N Engl J Med 354:2122-2130, 2006 https://doi.org/10.1056/NEJMoa054341
  10. Chapman AB, Bost JE, Torres VE, et al.: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7:479-486, 2012 https://doi.org/10.2215/CJN.09500911